Websites Hosted in dnadns3e.gene.com Nameserver
The Nameserver dnadns3e.gene.com have a IP Address of 72.34.133.50 which is hosted on United States of America.
Genentech
Breakthrough science. One moment, one day, one person at a time.
Genentech
Breakthrough science. One moment, one day, one person at a time.
Cancer Research & Information from Genentech BioOncology | BioOncology
Explore new research in cancer and learn how Genentech is transforming the way cancer is treated with innovative methods that target cancer and advance cancer research.
Cancer Education and Information | BioOncology
Explore new research in cancer and learn how Genentech is dedicated to investigating diverse biological pathways and disease targets.
Cancer Research & Information from Genentech BioOncology | BioOncology
Explore new research in cancer and learn how Genentech is transforming the way cancer is treated with innovative methods that target cancer and advance cancer research.
Avastin® (bevacizumab) Efficacy, Safety, Dosing & Prescribing Informat
Learn about Avastin® (bevacizumab) for FDA-approved indications. See full safety for more information.
HGH Injections | Nutropin AQ® (somatropin) injection, for subcutaneous
Find information about Nutropin AQ® (somatropin) injection, for subcutaneous use HGH Injection therapy, read about Nutropin GPS co-pay card and learn about the Nutropin AQ® regimen. See full safety for more information.
Rituxan® (rituximab) for RA, NHL, CLL, GPA, MPA, and PV
Find information about RITUXAN® (rituximab), a possible treatment for RA, NHL, CLL, GPA, MPA, and PV. See important safety including Boxed Warnings for more information.
Genentech Access Solutions | Health Care Professionals
Learn about Genentech Access Solutions, a resource that provides reliable, effective access and reimbursement support to assist your patients and practice.
HER2+ Cancer Treatment Option | Herceptin® (trastuzumab)
Find information about Herceptin®, a treatment for Early and Metastatic Breast Cancer and Stomach/GEJ Cancer. See full safety & Boxed Warnings for more information.
Pulmozyme® (dornase alfa) Cystic Fibrosis Treatment
Find information about cystic fibrosis and Pulmozyme, including how to manage your cystic fibrosis, your CF treatments, and options for financial support. INDICATION Pulmozyme (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improv
2-mg vial of t-PA — Official Site — Cathflo® Activase® (alteplase)
Learn more about Cathflo® Activase® (alteplase), the only lytic FDA-approved for restoring CVAD function for patients with occluded catheters. Cathflo® Activase® (alteplase) is indicated for the restoration of function to central venous access devices (CVADs) as assessed by the ability to withdraw blood. Cathflo® Activ
2-mg vial of t-PA — Official Site — Cathflo® Activase® (alteplase)
Learn more about Cathflo® Activase® (alteplase), the only lytic FDA-approved for restoring CVAD function for patients with occluded catheters. Cathflo® Activase® (alteplase) is indicated for the restoration of function to central venous access devices (CVADs) as assessed by the ability to withdraw blood. Cathflo® Activ
Activase® (Alteplase) for Acute Ischemic Stroke Treatment
Acute Ischemic Stroke Indication: Activase is indicated for the management of acute ischemic stroke in adults for improving neurological recovery and reducing the incidence of disability. Treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage
Lucentis® (ranibizumab injection) for Wet AMD, Diabetic Macular Edema
Find information and data for healthcare professionals about LUCENTIS® (ranibizumab injection) for the rapid and sustained improvement in vision for the treatment of wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. INDICATION LUCENTIS® (ranibizumab injection) is indicated for th
Lucentis® (ranibizumab injection) for Wet AMD, Diabetic Macular Edema
Find information and data for healthcare professionals about LUCENTIS® (ranibizumab injection) for the rapid and sustained improvement in vision for the treatment of wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. INDICATION LUCENTIS® (ranibizumab injection) is indicated for th
Research VEGF Ligand | BioOncology
Investigate research detailing VEGF ligand and its link to angiogenesis. The VEGF ligand may play an essential role throughout tumor development by helping vessels establish, grow and survive.
OCREVUS® (ocrelizumab) for Relapsing MS and Primary Progressive MS
Learn about OCREVUS® (ocrelizumab), a prescription medicine used to treat adults with relapsing or primary progressive multiple sclerosis. See full safety for more information.
Prescription Flu Treatment | XOFLUZA™ (baloxavir marboxil)
Learn about XOFLUZA™ (baloxavir marboxil), a one-dose prescription medicine used to treat the flu. See full safety for more information.
OCREVUS® (ocrelizumab) for Relapsing MS and Primary Progressive MS
Learn about OCREVUS® (ocrelizumab), a prescription medicine used to treat adults with relapsing or primary progressive multiple sclerosis. See full safety for more information.